Harrow Health ( (HROW) ) has released its Q2 earnings. Here is a breakdown of the information Harrow Health presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Harrow, Inc. is a prominent North American company specializing in ophthalmic disease management solutions, offering a wide array of products aimed at treating various eye conditions, including dry eye disease, cataracts, and retinal diseases.
In its second-quarter 2025 financial results, Harrow reported a significant revenue increase of 30% year-over-year, reaching $63.7 million. The company also achieved a GAAP net income of $5.0 million and an adjusted EBITDA of $17.0 million, indicating robust financial health and operational efficiency.
Key highlights from the quarter include the commercial success of VEVYE®, which saw a 66% growth in prescriptions, and the strategic acquisition of U.S. commercial rights for Samsung Bioepis’s ophthalmology biosimilar portfolio. Additionally, Harrow’s acquisition of BYQLOVI™ marks a significant expansion in its product offerings.
Looking ahead, Harrow’s management remains optimistic, projecting revenues to surpass $280 million for the year. The company is poised to leverage its expanding product portfolio and strategic alliances to drive further growth and profitability.